Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria Market

Paroxysmal Nocturnal Hemoglobinuria is considered an acquired disorder of the pluripotent hematopoietic stem cells. Red blood cells break apart due to this disorder. The breaking apart is usually known as "hemolysis." It occurs because the surface of an individual’s blood cells is missing a specific protein that protects them from the body's immune system.


Paroxysmal Nocturnal Hemoglobinuria Epidemiological Segmentation


The Epidemiological Segmentation of Paroxysmal Nocturnal Hemoglobinuria in 7MM from 2017 to 2030 is segmented into:-


  • Total Diagnosed Prevalent Cases of Paroxysmal Nocturnal Hemoglobinuria
  • Gender-Specific Cases of Paroxysmal Nocturnal Hemoglobinuria


Paroxysmal Nocturnal Hemoglobinuria Epidemiological Insights Observed in 2020


  • The total diagnosed Paroxysmal Nocturnal Hemoglobinuria prevalent cases was 8,385.
  • The diagnosed prevalent population of Paroxysmal Nocturnal Hemoglobinuria in the United States was 4,334.
  • The diagnosed prevalent population of Paroxysmal Nocturnal Hemoglobinuria in Germany was 1,280.
  • Paroxysmal Nocturnal Hemoglobinuria diagnosed prevalent population in the United Kingdom was observed to be 1,055.
  • The diagnosed Paroxysmal Nocturnal Hemoglobinuria prevalent population in Spain was 199.
  • In the United States, the Gender-specific cases of Paroxysmal Nocturnal Hemoglobinuria in males were observed to be 2,076 cases, and in females, it was observed to be 2,258 cases.


Paroxysmal Nocturnal Hemoglobinuria Market


The market size of Paroxysmal Nocturnal Hemoglobinuria in the 7MM was found to be USD 358.04 million in 2020.


Paroxysmal Nocturnal Hemoglobinuria Market Drivers


  • Abundant pipeline
  • Increasing disease understanding
  • Establishment of PNH registry


Paroxysmal Nocturnal Hemoglobinuria Market Barriers


  • Cost of therapy and reimbursement
  • Lack of multidisciplinary approach
  • Delay in diagnosis 


Paroxysmal Nocturnal Hemoglobinuria Emerging Drugs


The emerging drugs of the Paroxysmal Nocturnal Hemoglobinuria market are


  • Pegcetacoplan
  • Crovalimab
  • Iptacopan
  • Danicopan
  • REGN3918, and others


Paroxysmal Nocturnal Hemoglobinuria Key Players


The key players working in the Paroxysmal Nocturnal Hemoglobinuria market are 


  • Apellis Pharmaceuticals
  • Hoffmann-La Roche
  • Novartis
  • Alexion Pharmaceuticals
  • Regeneron Pharmaceuticals, and others